中生制药(01177.HK) 公布,集团与礼新医药联合开发的LM-108“CCR8单克隆抗体(单抗)”已被国家药监局药品审评中心纳入突破性治疗药物程序(BTD),用于联合特瑞普利单抗治疗既往接受一线标准治疗失败的CCR8阳性晚期胃╱胃食管结合部(G/GEJ)腺癌。
公司指,此前LM-108已于今年2月被国家药监局纳入BTD,用于经免疫检查点抑制剂治疗后疾病进展的微卫星高度不稳定(MSI-H)或错配修复缺陷(dMMR)晚期实体瘤。(ss/u)(港股报价延迟最少十五分钟。沽空资料截至 2025-06-26 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.